Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine ER as Adjunctive to Stimulants in ADHD
NCT01985581Phase 4Completed
- Sponsor
- JPM van Stralen Medicine Professional Corporation
- Start
- Oct 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of guanfacine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by JPM van Stralen Medicine Professional Corporation. Primary endpoint: Behavior Rating Inventory of Executive Function - Parent Version at 12 weeks. Started Oct 2013; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01985581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01985581.